Sight Sciences (SGHT) investor presentation summary

Mission and strategic focus

• Aims to develop transformative interventional technologies to elevate standards of eyecare and empower vision preservation.

• Focuses on innovation in two large, growing, and underserved markets: interventional glaucoma and interventional dry eye.

• Positioned at the intersection of interventional glaucoma and dry eye, leveraging synergies across both segments.

Interventional glaucoma market and technology

• Glaucoma is a leading cause of irreversible blindness, with over 4 million diagnosed patients and a $6 billion addressable U.S. market.

• OMNI Surgical System provides comprehensive, implant-free MIGS for primary open-angle glaucoma, treating all three resistance areas in the outflow pathway.

• OMNI is supported by robust clinical evidence, broad FDA indication, and over 370,000 procedures performed.

• Demonstrates consistent efficacy in both combination cataract and standalone procedures, with sustained intraocular pressure reduction and medication decrease.

• Addresses all six MIGS POAG categories, with a $5 billion standalone and $1 billion combination cataract opportunity.

Interventional dry eye market and technology

• Dry eye disease affects about 19 million U.S. patients, with a $2.4 billion market; up to 86% of cases are linked to meibomian gland dysfunction (MGD).

• TearCare is an FDA-cleared, open-eye, thermal-activated gland expression therapy targeting MGD, with over 70,000 procedures performed.

• SAHARA RCT showed TearCare's superiority over Restasis in tear break-up time and durable relief for up to two years with biannual treatments.

• TearCare offers economic savings for payors and is designed for scalable commercial growth, targeting 6,500 high-potential physicians.